Total trials
1,188
Active
232
Phase 3
59
Total enrollment
1,300,889
Pipeline matrix
Showing 40 of 59 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Saline | — | — | — | — | — | 2 | |
| Semaglutide | — | — | — | — | 2 | ||
| 0.5% bupivacaine | — | — | — | — | — | 1 | |
| Empagliflozin 25 MG Oral | — | — | — | — | — | 1 | |
| Empagliflozin 10 MG Oral Tablet [Jardiance] | — | — | — | — | — | 1 | |
| Cryoablation | — | — | — | — | — | 1 | |
| ESP Catheter | — | — | — | — | — | 1 | |
| Bupropion Extended Release Oral | — | — | — | — | — | 1 | |
| PENG block and cryoablation | — | — | — | — | — | 1 | |
| fascia iliaca compartment block | — | — | — | — | — | 1 | |
| Progesterone 200 MG Oral | — | — | — | — | — | 1 | |
| bupivacaine. | — | — | — | — | — | 1 | |
| empagliflozin | — | — | — | — | 2 | ||
| Modafinil | — | — | — | — | — | 2 | |
| standard of care | — | — | — | — | 2 | ||
| Choline bitartrate | — | — | — | — | 3 | ||
| Qsymia 7.5 miligrams (mg)-46 mg Extended Release | — | — | — | — | — | 1 | |
| D-serine solution | — | — | — | — | — | 1 | |
| LAmB B | — | — | — | — | — | 1 | |
| Posaconazole | — | — | — | — | — | 1 | |
| World Health Organization (WHO)-recommended SOC | — | — | — | — | — | 1 | |
| WHO-recommended SOC Itraconazole | — | — | — | — | — | 1 | |
| Oteseconazole - antifungal therapy 1 | — | — | — | — | — | 1 | |
| Turletricin injection - antifungal therapy 2 | — | — | — | — | — | 1 | |
| Turletricin Injection - antifungal therapy 3 | — | — | — | — | — | 1 | |
| Oteseconazole with Flucytosine - antifungal therapy 4 | — | — | — | — | — | 1 | |
| Lemborexant 10 mg | — | — | — | — | — | 1 | |
| Lemborexant 20mg | — | — | — | — | — | 1 | |
| Fisetin-dose 1 | — | — | — | — | — | 1 | |
| Fisetin-dose 2 | — | — | — | — | — | 1 | |
| Vancomycin, Neomycin and MTT | — | — | — | — | — | 1 | |
| Cytogam | — | — | — | — | — | 1 | |
| Formulation A | — | — | — | — | — | 1 | |
| Formulation B | — | — | — | — | — | 1 | |
| Formulation C | — | — | — | — | — | 1 | |
| pioglitazone-metformin | — | — | — | — | — | 1 | |
| Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation. | — | — | — | — | — | 1 | |
| MTP-101C | — | — | — | — | — | 1 | |
| MTP-101S | — | — | — | — | — | 1 | |
| efgartigimod | — | — | — | — | — | 1 |
19 more active programs hidden
Next readouts
- 2025-06-03
- 2025-10-27
- 2026-07-01
- 2026-07-28
- 2026-07-31
- 2026-08-23
- 2026-09-01
- 2026-09-01
- 2026-10-01
- 2026-10-30
Top conditions
- Obesity42
- Healthy32
- Cardiovascular Diseases30
- Stroke29
- Tobacco Use Disorder22
- Heart Diseases22
- Hypertension21
- Depression20
Frequently asked questions about University of Minnesota
- How many clinical trials does University of Minnesota have on ClinicalTrials.gov?
- University of Minnesota is listed as the lead sponsor on 1,188 clinical trials in ClinicalTrials.gov, 232 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Minnesota's trials are in Phase 3?
- 59 of University of Minnesota's trials are in Phase 3, spread across 59 active drug programs.
- What therapeutic areas does University of Minnesota focus on?
- University of Minnesota's most-studied conditions on ClinicalTrials.gov are Obesity, Healthy, Cardiovascular Diseases, Stroke, Tobacco Use Disorder.
- When are University of Minnesota's next clinical trial readouts?
- University of Minnesota has 10 upcoming primary-completion readouts tracked here; the soonest is “SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes”, expected around 2025-06-03.